Results 261 to 270 of about 1,459,292 (318)

Heterocyclic HIV-Protease Inhibitors

Current Medicinal Chemistry, 2013
In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors ...
CALUGI, CHIARA, GUARNA, ANTONIO, TRABOCCHI, ANDREA   +2 more
openaire   +3 more sources

Prodrugs of HIV Protease Inhibitors

Current Pharmaceutical Design, 2003
Despite the efficiency of the present polytherapies against AIDS, HIV replication continues indicating difficulties in drug adherence, drug-drug interactions, resistance issues, and the existence of reservoirs or sanctuaries for the virus. Moreover, most of the current FDA-approved HIV protease inhibitors (PIs) display disadvantageous physicochemical ...
Pierre, Vierling, Jacques, Greiner
openaire   +2 more sources

Peptidomimetic Inhibitors of HIV Protease

Current Topics in Medicinal Chemistry, 2004
There are currently (July, 2002) six protease inhibitors approved for the treatment of HIV infection, each of which can be classified as peptidomimetic in structure. These agents, when used in combination with other antiretroviral agents, produce a sustained decrease in viral load, often to levels below the limits of quantifiable detection, and a ...
John T, Randolph, David A, DeGoey
openaire   +2 more sources

Resistance to HIV protease inhibitors

Haemophilia, 1998
Summary. Resistance to the HIV‐1 protease inhibitor indinavir involves the accumulation of multiple amino acid substitutions in the viral protease. A minimum of 11 amino acid positions have been identified as potential contributors to phenotypic resistance.
C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, J. H. CONDRA   +5 more
openaire   +2 more sources

Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.

Current Topics in Medicinal Chemistry, 2019
Acquired Immunodeficiency Syndrome (AIDS) is a chronic disease characterized by multiple life-threatening illnesses caused by a retro-virus, Human Immunodeficiency Virus (HIV).
Chandrashekhar Voshavar
semanticscholar   +1 more source

Inhibitors of HIV-1 Protease

Journal of Enzyme Inhibition, 1992
The human immunodeficiency virus (HIV), the etiological agent for the acquired immune deficiency syndrome (AIDS), is a retrovirus which makes use of a virally-encoded aspartic protease to perform specific proteolytic processing of two of its gene products in order to form active enzymes and structural proteins within the mature virion.
openaire   +2 more sources

HIV-protease-inhibitors

Reactions weekly, 2021

semanticscholar   +1 more source

Perspectives in HIV Protease Inhibitors

1996
The therapy of HIV-1, the causative agent of AIDS, is limited today to a small number of different drugs, all of which are nucleoside analogues. Nucleoside analogues active against HIV are all inhibitors of reverse transcriptase (RT) and target primarily early events in the replication cycle of HIV.
openaire   +2 more sources

Screening efficacy of available HIV protease inhibitors on COVID-19 protease

, 2020
M. Mirzaei, K. Harismah, M. Da'i, E. Salarrezaei, Z. Roshandel   +4 more
semanticscholar   +1 more source

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

AIDS (London), 1998
A. Carr, K. Samaras, S. Burton, M. Law, J. Freund, D. Chisholm, D. Cooper   +6 more
semanticscholar   +1 more source